RhD prophylaxis failure in Rio de Janeiro, Brazil

Abstract

In this retrospective case series of 17 pregnant women, selftreatment of both baseline and new external anogenital warts with imiquimod 5% cream provided a complete response in 13 (76.4%) women. One patient experienced a partial response, giving a total response rate of 82.3%. In this small series, a complete response was achieved more rapidly during pregnancy (mean 5.1 weeks) than in non-pregnant women (12 weeks) [1]. External anogenital warts did not reoccur in patients with a complete response, although the follow-up time was short (9 weeks). This report of topical imiquimod 5% cream should be considered as a preliminary study because the relatively small number of subjects treated and short follow-up preclude generalization. Larger comparative clinical trials are needed to determine the therapeutic value and safety of topical imiquimod 5% cream for treating external anogenital warts in pregnancy.